SCHEMBL3594196

SCHEMBL3594196

NCC(CN1CCCC1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
MITF O75030 1/20 0.47
HTT P42858 1/20 0.47
RAB9A P51151 1/20 0.47
GFER P55789 1/20 0.47
PAX8 Q06710 1/20 0.47
ATM Q13315 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
GABBR2 O75899 2/20 0.46
GABBR1 Q9UBS5 2/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HTR2A P28223 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
POLB P06746 1/20 0.43
CYP2D6 P10635 5/20 0.43
OPRK1 P41145 2/20 0.43
KDM4E B2RXH2 1/20 0.42
MAPK1 P28482 1/20 0.42
CYP1A2 P05177 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2953077 0.90 CHRNB2 (0.49) ALDH1A1MITFHTTRAB9AGFER
SCHEMBL7402416 0.84 POLB (0.51) ALDH1A1MITFHTTRAB9AATM
SCHEMBL2950065 0.82 HTR2A (0.42) ALDH1A1HTTATMMEN1KMT2A
SCHEMBL11927945 0.81 ALDH1A1 (0.47) ALDH1A1MITFHTTRAB9AGFER
SCHEMBL3589625 0.81 ALDH1A1 (0.51) ALDH1A1MITFHTTRAB9AGFER
SCHEMBL4741508 0.81 MEN1 (0.55) ALDH1A1MEN1KMT2ACYP2D6CYP1A2
SCHEMBL2947190 0.80 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2MEN1KMT2APOLB
SCHEMBL7790826 0.80 ALDH1A1 (0.46) ALDH1A1MITFHTTRAB9AGFER
SCHEMBL8195078 0.79 TSHR (0.51) HTTRAB9ASMN1; SMN2KMT2ATSHR
SCHEMBL6614794 0.78 SMN1; SMN2 (0.52) ALDH1A1MITFHTTRAB9AGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7704996-B2 Compounds and compositions useful as cathepsin S inhibitors NOVARTIS AG (CH) 2010-04-27 US disclosed
US-7704996-B2 Compounds and compositions useful as cathepsin S inhibitors NOVARTIS AG (CH) 2010-04-27 US disclosed
US-7704996-B2 Compounds and compositions useful as cathepsin S inhibitors NOVARTIS AG (CH) 2010-04-27 US disclosed
US-20090048230-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS NOVARTIS AG (CH) 2009-02-19 US disclosed
US-20090048230-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS NOVARTIS AG (CH) 2009-02-19 US disclosed
US-20090048230-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS NOVARTIS AG (CH) 2009-02-19 US disclosed
WO-2006018284-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS NOVARTIS AG (CH) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048230-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS CTSS, CTSZ, CTSF ALDH1A1 4107/4885MITF 1899/4885HTT 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.